COGT•benzinga•
Cogent Biosciences Announces SUMMIT Continues To Showcase Powerful Symptomatic Improvement In NonAdvanced Systemic Mastocytosis Patients; 65% Mean Improvement In Total Symptom Score At 48 Weeks, Including 88% Of Patients Achieving At Least A 50% Reduction
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 27, 2025 by benzinga